405 related articles for article (PubMed ID: 17942919)
1. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
2. Measurements of TSC2 GAP activity toward Rheb.
Li Y; Inoki K; Vikis H; Guan KL
Methods Enzymol; 2006; 407():46-54. PubMed ID: 16757313
[TBL] [Abstract][Full Text] [Related]
3. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
4. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
6. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
9. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
10. Rheb activation of mTOR and S6K1 signaling.
Hanrahan J; Blenis J
Methods Enzymol; 2006; 407():542-55. PubMed ID: 16757352
[TBL] [Abstract][Full Text] [Related]
11. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.
Avruch J; Hara K; Lin Y; Liu M; Long X; Ortiz-Vega S; Yonezawa K
Oncogene; 2006 Oct; 25(48):6361-72. PubMed ID: 17041622
[TBL] [Abstract][Full Text] [Related]
12. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
[TBL] [Abstract][Full Text] [Related]
14. Rheb binds and regulates the mTOR kinase.
Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J
Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the small GTPase Rheb by amino acids.
Roccio M; Bos JL; Zwartkruis FJ
Oncogene; 2006 Feb; 25(5):657-64. PubMed ID: 16170341
[TBL] [Abstract][Full Text] [Related]
16. Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.
Lacher MD; Pincheira R; Zhu Z; Camoretti-Mercado B; Matli M; Warren RS; Castro AF
Oncogene; 2010 Dec; 29(50):6543-56. PubMed ID: 20818424
[TBL] [Abstract][Full Text] [Related]
17. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1.
Tee AR; Blenis J; Proud CG
FEBS Lett; 2005 Aug; 579(21):4763-8. PubMed ID: 16098514
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
[TBL] [Abstract][Full Text] [Related]
19. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
[TBL] [Abstract][Full Text] [Related]
20. Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of tuberin.
Lesma E; Ancona S; Orpianesi E; Grande V; Di Giulio AM; Gorio A
J Pharmacol Exp Ther; 2013 May; 345(2):180-8. PubMed ID: 23426956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]